Tucaxen 150mg Tablet: Targeted Therapy for HER2-Positive Breast Cancer

Tucaxen 150mg Tablet contains Tucatinib, a targeted therapy specifically designed to treat HER2-positive breast cancer. This medication works by inhibiting the HER2 protein, which plays a crucial role in the growth and spread of certain types of breast cancer cells.

Key Features:

• Targeted Action: Tucaxen selectively inhibits the HER2 protein, effectively slowing down or stopping the proliferation of cancer cells.
• Combination Therapy: Often prescribed alongside trastuzumab and capecitabine, enhancing the overall efficacy against advanced or metastatic HER2-positive breast cancer.

Usage:

The recommended dosage is 300 mg daily, divided into two 150 mg doses taken approximately 12 hours apart. Tucaxen can be taken with or without food. It’s essential to follow your healthcare provider’s instructions regarding dosage and administration.

Potential Side Effects:

• Common: Diarrhea, fatigue, nausea, vomiting, and abdominal pain.
• Serious: Liver toxicity and severe diarrhea. Regular monitoring of liver function tests is recommended during treatment.

Precautions:

• Pregnancy and Breastfeeding: Tucaxen may harm an unborn baby; avoid use during pregnancy and breastfeeding.
• Drug Interactions: Inform your doctor about all medications and supplements you’re taking to prevent potential interactions.

Availability:

Tucaxen 150mg Tablets are available in packs of 30 tablets. For more information or to place an order, visit MedicineWalyDost.com.

Product Tags: Tucaxen 150mg, Tucatinib, HER2-Positive Breast Cancer Treatment, Targeted Therapy, Advanced Breast Cancer Medication, MedicineWalyDost.com